Building high-performance genetic technologies that transform patient lives
Dyno Therapeutics applies AI and high-throughput in vivo experimentation to engineer novel AAV capsids for gene therapy, creating vectors with improved tissue targeting, safety, and efficacy. The company operates a partnership-centric model, licensing its capsid technology to pharma leaders including Novartis, Sarepta, Roche, Spark, and Astellas under deals collectively valued at over $4 billion.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2021
May 2020
Create a free account to see which investors have funded this company.
Create Free Account
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
